

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Vericiguat

Item No. 35253

CAS Registry No.: 1350653-20-1

Formal Name: N-[4,6-diamino-2-[5-fluoro-1-[(2-

> fluorophenyl)methyl]-1H-pyrazolo[3,4-b] pyridin-3-yl]-5-pyrimidinyl]-carbamic acid,

methyl ester

Synonyms: BAY-1021189, MK-1242

MF: $C_{19}H_{16}F_2N_8O_2$

426.4 FW: **Purity:** ≥98% λ_{max} : 257 nm UV/Vis.: Supplied as: A solid -20°C Storage: ≥4 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vericiguat is supplied as a solid. A stock solution may be made by dissolving the vericiguat in the solvent of choice, which should be purged with an inert gas. Vericiguat is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of vericiguat in these solvents is approximately 1 mg/ml.

Description

Vericiguat is a stimulator of soluble guanylyl cyclase (sGC).¹ It stimulates the formation of cGMP in CHO cells expressing recombinant rat sGC in the absence and presence of the nitric oxide (NO) donor SNAP (Item No. 82250; EC₅₀s = 1,005 and 39 nM, respectively), an effect that can be reversed by the sGC inhibitor ODQ (Item No. 81410). Vericiguat inhibits phenylephrine-induced contractions in isolated rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings (IC50s = 798, 692, and 3,072 nM, respectively), as well as decreases the coronary perfusion pressure in isolated perfused rat hearts in a concentration-dependent manner. It decreases proteinuria and increases survival in rats expressing mouse renin ((mRenR2)27), a transgenic model for hypertension, when administered at doses of 3 or 10 mg/kg. Formulations containing vericiguat have been used in the treatment of heart failure.

Reference

1. Follmann, M., Ackerstaff, J., Redlich, G., et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J. Med. Chem. 60(12), 5146-5161 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM